Spore.Bio Secures $23M Series A to Scale AI-Powered Bacteria Detection Technology
Spore.Bio has successfully validated its first prototypes in its lab and is now working with 200+ factories.
Company Name: Spore.Bio
Location: Paris, France
Industry: Biotech
Funding Details:
- Amount: $23M (Series A)
- Total Funding to Date: $31.3M
- Investors:
- Lead: Singular
- Participants: Point 72 Ventures, 1st Kind Ventures (Peugeot Family Office), Station F, Lord David Prior (ex-Chair NHS)
- Existing Investors: LocalGlobe, No Label Ventures, Famille C (Clarins Family Office)
Purpose of Investment:
- Double workforce from 25 to 50 scientists and engineers
- Scale up industrialization process
- Expand beyond Food & Beverage into Pharma and Cosmetics
- Iterate with customers and prepare for commercialization by year-end
Leadership:
- CEO: Amine Raji (former Nestlé manufacturing engineer)
- CTO: Maxime Mistretta (PhD, Pasteur Institute)
- COO: Mohamed Tazi (second-time founder, previously sold Gymlib to EGYM)
Product:
Spore.Bio develops proprietary AI-powered testing technology that combines machine learning and microbiology to detect and quantify bacteria with speed and precision.
About the Company:
Founded in 2023, Spore.Bio has successfully validated its first prototypes in its lab and is now working with 200+ factories. Beyond Food & Beverage, the company is expanding into Pharma and Cosmetics while securing a strategic academic partnership with the Pasteur Institute to enhance its capabilities.
Future Plans:
With this funding, Spore.Bio will accelerate its commercialization efforts, bolster its technology with Pasteur Institute’s biobank, and capitalize on its recent acquisition of competitor Greentropism—which previously raised €3M—to enhance its technical expertise and intellectual property.
